Review
Immunology
Butuo Li, Chao Jiang, Linlin Pang, Bing Zou, Mingjun Ding, Xindong Sun, Jinming Yu, Linlin Wang
Summary: The combination of immune checkpoint inhibitors and thoracic radiotherapy in NSCLC patients shows significant clinical activity, with most adverse events being tolerable. Pneumonitis, as the most common high-grade AE, requires close attention. The toxicity profiles of PD-1 and PD-L1 inhibitors are similar, and there is no significant difference between concurrent and sequential treatment in terms of adverse event incidence.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biology
Liliang Xia, Hui Wang, Mingjiao Sun, Yi Yang, Chengcheng Yao, Sheng He, Huangqi Duan, Weimin Xia, Ruiming Sun, Yaxian Yao, Zhiwei Chen, Qiong Zhao, Hong Li, Shun Lu, Ying Wang
Summary: This study investigates peripheral CD4(+) T cell signatures in advanced NSCLC patients receiving anti-PD-1/PD-L1 treatments, finding that certain subsets of these cells are associated with treatment response and progression-free survival. Logistic regression analysis identified IFN-gamma-producing CD4(+) Tn cells and PD-1(+)CD4(+) Tm cells as significant predictive biomarkers, with the potential for combination therapy using anti-PD-1 and anti-PD-L1 in advanced NSCLC patients.
SCIENCE CHINA-LIFE SCIENCES
(2021)
Article
Oncology
Kinan El Husseini, Nicolas Piton, Marielle De Marchi, Antoine Gregoire, Roman Vion, Pierre Blavier, Luc Thiberville, Jean-Marc Baste, Florian Guisier
Summary: This study confirms the safety of lung resection in patients following preoperative ICI treatment, with higher rates of major pathological response and disease-free survival in the ICI cohort. The study suggests that preoperative ICI treatment does not lead to higher perioperative morbidity or mortality.
Review
Oncology
Shuang Zhang, Ying Cheng
Summary: Small-cell lung cancer (SCLC) is a deadly type of lung cancer with limited treatment options. Recent studies have shown that adding immunotherapy to chemotherapy can improve the survival of patients with extensive-stage SCLC, establishing a new standard of first-line treatment. This article reviews the current status of first-line immunotherapy, strategies to enhance its efficacy, and the identification of potential predictive biomarkers for immunotherapy in SCLC.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Eric Pasqualotto, Francisco Cezar Aquino de Moraes, Matheus Pedrotti Chavez, Maria Eduarda Cavalcanti Souza, Anna Luiza Soares de Oliveira Rodrigues, Rafael Oliva Morgado Ferreira, Lucca Moreira Lopes, Artur Menegaz de Almeida, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos
Summary: The combination of PD-1/PD-L1 inhibitors with chemotherapy in resectable stage non-small cell lung cancer shows promising efficacy in improving overall survival, event-free survival, and pathological response. The neoadjuvant use of these agents is associated with increased survival and pathological response but with a manageable safety profile.
Article
Oncology
Mohamed Eltahir, Johan Isaksson, Johanna Sofia Margareta Mattsson, Klas Karre, Johan Botling, Martin Lord, Sara M. Mangsbo, Patrick Micke
Summary: Immunotherapy in lung cancer patients leads to varying responses, with some showing higher or lower levels of immune markers in blood samples correlating to better survival. A study evaluated a blood-based test to predict treatment efficacy, finding that certain plasma protein levels could predict response better than traditional PD-L1 scoring. The use of multiplex plasma protein levels as a tool for anti-PD-(L)1 response prediction in NSCLC was supported by the findings, with specific protein signatures identified for response prediction to anti-PD-(L)1 therapy.
Article
Pharmacology & Pharmacy
Lingling Li, Tingting Liu, Qingyan Liu, Shuai Mu, Haitao Tao, Xuhui Yang, Yao Li, Qi Xiong, Lijie Wang, Yi Hu
Summary: The study demonstrates the efficacy of rechallenge of PD-1/PD-L1 inhibitors in SCLC patients, especially in the first-line initial immunotherapy subgroup or patients with SD/PD response to the initial immunotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Rola El Sayed, Normand Blais
Summary: Small cell lung cancer is a disease with aggressive features and limited treatment options. Immunotherapy has changed the treatment landscape for many cancers, including SCLC, but questions remain on how to best implement and enhance responses to this treatment.
Article
Immunology
Qiao Yang, Mingjing Chen, Jiaoyang Gu, Kai Niu, Xianlan Zhao, Linpeng Zheng, Zihan Xu, Yongxin Yu, Feng Li, Lingxin Meng, Zhengtang Chen, Wenlei Zhuo, Luping Zhang, Jianguo Sun
Summary: This study found that increased expression of PD-L1 mRNA and exoPD-L1 in the early stage of ICIs treatment may serve as positive biomarkers of efficacy and overall survival in advanced NSCLC patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Jianqiong Yin, Yuanjun Wu, Xue Yang, Lu Gan, Jianxin Xue
Summary: Immune checkpoint inhibitors (ICIs) are drugs used to treat non-small-cell lung cancer by enhancing the function of T cells and producing long-lasting antitumor effects. However, ICIs can cause immune-related adverse events (irAEs), including severe pneumonia. Currently, the diagnosis and mechanisms of checkpoint inhibitor pneumonitis (CIP) are not well understood.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ying Cheng, James Chih-Hsin Yang, Isamu Okamoto, Li Zhang, Jie Hu, Donglin Wang, Chengping Hu, Jianying Zhou, Lin Wu, Lejie Cao, Jiwei Liu, Helong Zhang, Hong Sun, Ziping Wang, Hongjun Gao, Yan Yan, Suijun Xiao, Jianxin Lin, M. Catherine Pietanza, Takayasu Kurata
Summary: The aim of this study was to evaluate the efficacy of pembrolizumab plus chemotherapy in East Asian patients with untreated advanced/metastatic NSCLC and PD-L1 tumor proportion score <1%. The results showed that pembrolizumab plus chemotherapy had better overall survival and progression-free survival compared to chemotherapy alone. Therefore, the use of pembrolizumab in combination with chemotherapy is supported for East Asian patients with PD-L1-negative, advanced NSCLC.
Review
Oncology
Bryan Oronsky, Nacer Abrouk, Scott Caroen, Michelle Lybeck, Xiaoning Guo, Xiaohui Wang, Zhongwen Yu, Tony Reid
Summary: For close to 40 years, small-cell lung cancer (SCLC) has been stagnant with no progress or effective treatments. However, between 2018 and 2021, several new drugs were approved, bringing hope to SCLC patients.
Article
Oncology
Antonella Fameli, Valerio Nardone, Mojtaba Shekarkar Azgomi, Giovanna Bianco, Claudia Gandolfo, Bianca Maria Oliva, Marika Monoriti, Rita Emilena Saladino, Antonella Falzea, Caterina Romeo, Natale Daniele Calandruccio, Domenico Azzarello, Rocco Giannicola, Luigi Pirtoli, Antonio Giordano, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Grazia Cusi, Luciano Mutti, Cirino Botta, Pierpaolo Correale
Summary: Peripheral immune-checkpoint blockade with PD-1/PD-L1 antibodies is a promising treatment strategy for mNSCLC patients. This study investigates the impact of PD-1/PD-L1 blockade on specific immune cell subsets and suggests a correlation between immune subpopulation deregulation and autoimmunity.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, Research & Experimental
Elina Khatoon, Dey Parama, Aviral Kumar, Mohammed S. Alqahtani, Mohamed Abbas, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
Summary: Ovarian cancer is a deadly gynecological cancer with a low survival rate. Recent advancements in immunotherapy, particularly targeting the PD-1/PD-L1 axis, have shown promise in enhancing anti-tumor activity. Combinatorial treatment with small molecule inhibitors has also shown improved efficacy.
Article
Oncology
Helene Doubre, Laurent Greillier, Gregoire Justeau, Charles Ricordel, Aurelie Swalduz, Hubert Curcio, Olivier Bylicki, Jean-Bernard Auliac, Florian Guisier, Laurence Bigay-Game, Marie Bernardi, Julian Pinsolle, Karim Amrane, Chantal Decroisette, Renaud Descourt, Christos Chouaid, Margaux Geier
Summary: Limited data are available on the impact of venous thrombotic events (VTE) in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immunotherapy. This study analyzed the incidence of VTE and its influence on patient characteristics and outcomes in a cohort of mNSCLC patients receiving first-line treatment with pembrolizumab monotherapy. The results showed a relatively high incidence of VTE in these patients, with younger age, long-term corticosteroid treatment, and liver metastases being associated with higher risk. The occurrence of VTE was found to significantly reduce progression-free survival (PFS), but did not have a significant impact on overall survival (OS).
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Venu Madhav Konala, Sreedhar Adapa, Wilbert S. Aronow
Summary: Bladder cancer is a common cancer and cisplatin-based chemotherapy is the standard treatment. The development of immunotherapy has been a significant breakthrough and it is approved as a second-line treatment for bladder cancer. However, its first-line use is limited to patients who cannot tolerate cisplatin treatment.
AMERICAN JOURNAL OF THERAPEUTICS
(2022)
Article
Virology
Vijay Gayam, Venu M. Konala, Srikanth Naramala, Pavani Reddy Garlapati, Mohamed A. Merghani, Nirajan Regmi, Mamtha Balla, Sreedhar Adapa
JOURNAL OF MEDICAL VIROLOGY
(2020)
Letter
Pharmacology & Pharmacy
Nikhil Agrawal, Neil Roy, Srikanth Naramala, Venu Madhav Konala, Sreedhar Adapa, Hemant Dhingra, Wilbert S. Aronow
AMERICAN JOURNAL OF THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Vikram Sangani, Mytri Pokal, Mamtha Balla, Ganesh Prasad Merugu, Sreedhar Adapa, Srikanth Naramala, Venu Madhav Konala
Summary: Neuromyelitis Optica spectrum disorder is a severe autoimmune demyelinating disease commonly affecting the optic nerve and spinal cord, with possible comorbidity with other autoimmune disorders like SLE. Timely diagnosis and treatment are crucial in reducing symptoms and complications for patients with this disorder.
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES
(2021)
Article
Medicine, General & Internal
Vikram Sangani, Mytri Pokal, Mamtha Balla, Ganesh Prasad Merugu, Waleed Khokher, Vijay Gayam, Venu Madhav Konala
Summary: Fat embolism syndrome is a life-threatening complication of sickle beta-thalassemia, primarily seen in milder versions of sickle cell disease. Prompt diagnosis and early initiation of treatment can reduce morbidity and mortality, with red cell exchange transfusion being the mainstay of therapy. However, mortality and neurological sequelae remain high despite increased use of red cell exchange transfusion in recent years.
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS
(2021)
Article
Medicine, General & Internal
Vikram Sangani, Mytri Pokal, Mamtha Balla, Ganesh Prasad Merugu, Sreedhar Adapa, Srikanth Naramala, Venu Madhav Konala
Summary: Immune checkpoint inhibitor-related neurotoxicity causing Guillain Barre Syndrome is rare, but can be fatal if not promptly diagnosed and managed. Prompt recognition and treatment of neurological autoimmune side effects is crucial with the increasing use of immunotherapy for cancer management.
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES
(2021)
Article
Medicine, General & Internal
Vikram Sangani, Mytri Pokal, Mamtha Balla, Vijay Gayam, Venu Madhav Konala
Summary: Paget-Schroetter syndrome is a rare condition involving upper extremity deep vein thrombosis, commonly affecting young individuals. Timely management is crucial to prevent long-term disabilities and recurrent thromboembolism. Surgical decompression may be effective, but further research is needed for clarification.
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS
(2021)
Meeting Abstract
Oncology
Sara Ashraf, Venu Madhav Konala, Mohammad Ali Syed Jafri
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Letter
Medicine, General & Internal
Sasmit Roy, Venu Madhav Konala, Thurein Kyaw, Sandipan Chakraborty, Srikanth Naramala, Vijay Gayam, Sreedhar Adapa, Subhasish Bose
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS
(2020)
Review
Medicine, General & Internal
Amrendra Mandal, Venu Madhav Konala, Sreedhar Adapa, Srikanth Naramala, Vijay Gayam
CUREUS JOURNAL OF MEDICAL SCIENCE
(2020)
Article
Medicine, General & Internal
Sreedhar Adapa, Srikanth Naramala, Vijay Gayam, Narayana Murty Koduri, Subba Rao Daggubati, Pallav Patel, Venu Madhav Konala
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS
(2020)
Article
Medicine, General & Internal
Subhasish Bose, Sreedhar Adapa, Venu Madhav Konala, Hemapriya Gopalreddy, Salim Sohail, Srikanth Naramala, Hema Kondakindi, Vijayadershan Muppidi, Manoj Ramachandran, Peter J. Juran, Narothama Reddy Aeddula
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS
(2020)
Article
Medicine, General & Internal
Avantika Chenna, Venu Madhav Konala, Vijay Gayam, Srikanth Naramala, Sreedhar Adapa
CUREUS JOURNAL OF MEDICAL SCIENCE
(2020)
Article
Medicine, General & Internal
Keerti Deepika, Ramesh Adhikari, Sreedhar Adapa, Srikanth Naramala, Venu Madhav Konala
CUREUS JOURNAL OF MEDICAL SCIENCE
(2020)